Drugs / AS03
AS03
Trials 21 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04405908 Comparator | Jun 2020 → Oct 2021 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05289037 Background | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03318315 Background | Feb 2018 → Jul 2019 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS03 | “Participants received one intramuscular (IM) injection (total volume 0.7 mL) of 15 μg/strain of the Quadrivalent virus-like particle (VLP) Influenza Vaccine adjuvanted with...” NCT04622592 ↗19“intramuscular subvirion inactivated monovalent influenza A/H5N1 (HA of A/Indonesia/05/2005) virus vaccine manufactured by Sanofi Pasteur administered at 3.75 mcg per dose given...” NCT01573312 ↗ |
| Known as | AS03 Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01317758 ↗ |
| Known as | D-SUIV cH8/1N1+AS03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275389 ↗ |
| Modality | Other / unclassified | “Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)” NCT01317758 ↗ |
| Route | Intramuscular | “Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.” NCT01573312 ↗ |